[Diffuse large B-cell lymphoma: current treatment strategy and future outlook].

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma in Japan. Approximately half of all patients can be cured with frontline rituximab-containing chemoimmunotherapy. However, patients with relapsed or refractory disease after standard chemotherapy often have a poor prognosis. Various novel therapies have been developed to improve outcomes in this population. In particular, immunotherapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody therapies have significantly transformed the treatment landscape for relapsed or refractory DLBCL. Several ongoing clinical trials are also investigating incorporation of these novel agents into frontline treatment regimens. This review outlines current treatment strategies for DLBCL and highlights recent advances in clinical development, with a focus on emerging immunotherapies.